Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.

Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, Finn MB, Hoyle R, Keyser J, Lefton KB, Robinson GO, Serrano JR, Silverman AP, Guo JL, Getz J, Henne K, Leyns CE, Gallardo G, Ulrich JD, Sullivan PM, Lerner EP, Hudry E, Sweeney ZK, Dennis MS, Hyman BT, Watts RJ, Holtzman DM.

J Clin Invest. 2018 May 1;128(5):2144-2155. doi: 10.1172/JCI96429. Epub 2018 Mar 30.

2.

Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis.

Kapur S, Silverman AP, Ye AZ, Papo N, Jindal D, Blumenkranz MS, Cochran JR.

Bioeng Transl Med. 2017 Mar;2(1):81-91. doi: 10.1002/btm2.10051. Epub 2017 Feb 17.

3.

111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis.

Jiang L, Miao Z, Kimura RH, Silverman AP, Ren G, Liu H, Lu H, Cochran JR, Cheng Z.

J Biomed Biotechnol. 2012;2012:368075. doi: 10.1155/2012/368075. Epub 2012 Apr 11.

4.

Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.

Papo N, Silverman AP, Lahti JL, Cochran JR.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14067-72. doi: 10.1073/pnas.1016635108. Epub 2011 Aug 8.

5.

Cystine-knot peptides engineered with specificities for α(IIb)β(3) or α(IIb)β(3) and α(v)β(3) integrins are potent inhibitors of platelet aggregation.

Silverman AP, Kariolis MS, Cochran JR.

J Mol Recognit. 2011 Jan-Feb;24(1):127-35. doi: 10.1002/jmr.1036.

PMID:
21194123
6.

Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin.

Jiang L, Kimura RH, Miao Z, Silverman AP, Ren G, Liu H, Li P, Gambhir SS, Cochran JR, Cheng Z.

J Nucl Med. 2010 Feb;51(2):251-258. doi: 10.2967/jnumed.109.069831.

7.

Interrogating and predicting tolerated sequence diversity in protein folds: application to E. elaterium trypsin inhibitor-II cystine-knot miniprotein.

Lahti JL, Silverman AP, Cochran JR.

PLoS Comput Biol. 2009 Sep;5(9):e1000499. doi: 10.1371/journal.pcbi.1000499. Epub 2009 Sep 4.

8.

Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities.

Silverman AP, Levin AM, Lahti JL, Cochran JR.

J Mol Biol. 2009 Jan 30;385(4):1064-75. doi: 10.1016/j.jmb.2008.11.004. Epub 2008 Nov 12.

9.

Quenched autoligation probes.

Silverman AP, Abe H, Kool ET.

Methods Mol Biol. 2008;429:161-70. doi: 10.1007/978-1-60327-040-3_11.

PMID:
18695965
10.

Developing therapeutic proteins by engineering ligand-receptor interactions.

Jones DS, Silverman AP, Cochran JR.

Trends Biotechnol. 2008 Sep;26(9):498-505. doi: 10.1016/j.tibtech.2008.05.009. Epub 2008 Jul 31. Review.

PMID:
18675482
11.

Steric effects in RNA interference: probing the influence of nucleobase size and shape.

Somoza A, Silverman AP, Miller RM, Chelliserrykattil J, Kool ET.

Chemistry. 2008;14(26):7978-87. doi: 10.1002/chem.200800837.

PMID:
18624291
12.

Probing the active site steric flexibility of HIV-1 reverse transcriptase: different constraints for DNA- versus RNA-templated synthesis.

Silverman AP, Garforth SJ, Prasad VR, Kool ET.

Biochemistry. 2008 Apr 22;47(16):4800-7. doi: 10.1021/bi702427y. Epub 2008 Mar 27.

13.

Steric and electrostatic effects in DNA synthesis by the SOS-induced DNA polymerases II and IV of Escherichia coli.

Silverman AP, Jiang Q, Goodman MF, Kool ET.

Biochemistry. 2007 Dec 4;46(48):13874-81. Epub 2007 Nov 8.

14.

RNA probes of steric effects in active sites: high flexibility of HIV-1 reverse transcriptase.

Silverman AP, Kool ET.

J Am Chem Soc. 2007 Sep 5;129(35):10626-7. Epub 2007 Aug 14. No abstract available.

PMID:
17696348
15.
16.

Oligonucleotide probes for RNA-targeted fluorescence in situ hybridization.

Silverman AP, Kool ET.

Adv Clin Chem. 2007;43:79-115. Review.

PMID:
17249381
17.

RNA-templated chemistry in cells: discrimination of Escherichia, Shigella and Salmonella bacterial strains with a new two-color FRET strategy.

Silverman AP, Baron EJ, Kool ET.

Chembiochem. 2006 Dec;7(12):1890-4. No abstract available.

PMID:
17031884
18.

Detecting RNA and DNA with templated chemical reactions.

Silverman AP, Kool ET.

Chem Rev. 2006 Sep;106(9):3775-89. Review. No abstract available.

PMID:
16967920
19.
20.

Quenched probes for highly specific detection of cellular RNAs.

Silverman AP, Kool ET.

Trends Biotechnol. 2005 May;23(5):225-30. Review.

PMID:
15865999
21.

2.4-A crystal structure of the asymmetric platinum complex [Pt(ammine)(cyclohexylamine)]2+ bound to a dodecamer DNA duplex.

Silverman AP, Bu W, Cohen SM, Lippard SJ.

J Biol Chem. 2002 Dec 20;277(51):49743-9. Epub 2002 Oct 10.

22.
23.

High-throughput synthesis and screening of platinum drug candidates.

Ziegler CJ, Silverman AP, Lippard SJ.

J Biol Inorg Chem. 2000 Dec;5(6):774-83.

PMID:
11129005
24.

An ethologist's approach to behavioural toxicology.

Silverman AP.

Neurotoxicol Teratol. 1988 Mar-Apr;10(2):85-92.

PMID:
3398827
25.

General toxicology of tin and its organic compounds.

Krigman MR, Silverman AP.

Neurotoxicology. 1984 Summer;5(2):129-39. Review.

PMID:
6390260
26.

Early change and adaptation in the social behaviour or rats given methyl mercury in the diet.

Silverman AP, Banham PB, Extance K, Williams H.

Neurotoxicology. 1981 Oct;2(2):269-81.

PMID:
7198756
27.

Rodents' defence against cigarette smoke.

Silverman AP.

Anim Behav. 1978 Nov;26(4):1279-81. No abstract available.

PMID:
742758
28.

Nitrous oxide in practical classes [proceedings].

Silverman AP, Steinberg H.

Br J Pharmacol. 1978 Jun;63(2):409P. No abstract available.

29.

A behavioural test applied in an acute toxicity screen [proceedings].

Silverman AP.

Br J Pharmacol. 1978 Jun;63(2):349P-350P. No abstract available.

30.

Behavioural changes in rats suggesting drug-induced headache [proceedings].

Silverman AP.

Br J Pharmacol. 1976 Nov;58(3):439P-440P. No abstract available.

31.

Behaviour of rats exposed to trichloroethylene vapour.

Silverman AP, Williams H.

Br J Ind Med. 1975 Nov;32(4):308-15.

32.

Behaviour of rats given a "smoking dose" of nicotine.

Silverman AP.

Anim Behav. 1971 Feb;19(1):67-74. No abstract available.

PMID:
5170040
33.

A laboratory model for behaviour as an indicator of toxicity.

Silverman AP.

Ciba Found Study Group. 1970;35:25-40. No abstract available.

PMID:
5525678
34.

The neuroleptics. 5. Animal behavior.

Buser P, Cook L, Giurgea C, Jacobsen E, Ray OS, Richelle M, Silverman AP, Stein L, Votava Z.

Mod Probl Pharmacopsychiatry. 1970;5:85-108. No abstract available.

PMID:
5005610
35.

Behavioural effects of a "smoking dose" of nicotine in rats.

Silverman AP.

Br J Pharmacol. 1969 Oct;37(2):506P-507P. No abstract available.

36.

Barbiturates, lysergic acid diethylamide, and the social behaviour of laboratory rats.

Silverman AP.

Psychopharmacologia. 1966;10(2):155-71. No abstract available.

PMID:
6010531
37.

The social behaviour of laboratory rats and the action of chlorpromazine and other drugs.

Silverman AP.

Behaviour. 1966;27(1):1-38. No abstract available.

PMID:
5939036
38.

ETHOLOGICAL AND STATISTICAL ANALYSIS OF DRUG EFFECTS ON THE SOCIAL BEHAVIOUR OF LABORATORY RATS.

SILVERMAN AP.

Br J Pharmacol Chemother. 1965 Apr;24:579-90. No abstract available.

Supplemental Content

Loading ...
Support Center